J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
Johnson & Johnson kicked off Q1 earnings season with a “modest” beat, raking in $24.1 billion in sales as it targets $100 billion in revenue in 2026. J&J, as always, is the first to report results from a first quarter that has seen a wave of deals across biopharma; this M&A rush is expected to headline investor calls as more companies, including Novo Nordisk and Eli Lilly, report their Q1 results in the coming days. Meanwhile, IPOs are also on an upswing, with Kailera Therapeutics eyeing a raise that could reach as high as $533 million.
On the regulatory front, Replimune failed for a second…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.